Phase I Study of Human Von Willebrand Factor for Von Willebrand's Disease

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00004667

Enrollment

Registered

2000-02-25

Start date

1993-10-31

Completion date

Unknown

Last updated

2005-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Von Willebrand's Disease

Keywords

hematologic disorders, rare disease, von Willebrand's disease

Brief summary

OBJECTIVES: I. Evaluate the effect of a new von Willebrand factor concentrate on bleeding time, in vivo recovery, and circulating half-life of the infused factor in patients with von Willebrand's disease. II. Assess the safety of von Willebrand factor in these patients.

Detailed description

PROTOCOL OUTLINE: Patients receive 1 dose of von Willebrand factor concentrate. Timed blood studies are performed for the next 96 hours. Patients are followed every 2 weeks for 16 weeks, and at 24, 36, and 52 weeks.

Interventions

DRUGvon Willebrand factor

Study design

Primary purpose

TREATMENT

Eligibility

Sex/Gender

ALL

Age

0 Years to No maximum

Healthy volunteers

Inclusion criteria

PROTOCOL ENTRY CRITERIA: * von Willebrand's disease

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026